Advertisement

Topics

Latest "Global Polyalkene Glycol Based Lubricants Market Research Report" News Stories - Page: 2

18:13 EDT 22nd March 2019 | BioPortfolio

Here are the most relevant search results for "Global Polyalkene Glycol Based Lubricants Market Research Report" found in our extensive news archives from over 250 global news sources.

More Information about Global Polyalkene Glycol Based Lubricants Market Research Report on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Global Polyalkene Glycol Based Lubricants Market Research Report for you to read. Along with our medical data and news we also list Global Polyalkene Glycol Based Lubricants Market Research Report Clinical Trials, which are updated daily. BioPortfolio also has a large database of Global Polyalkene Glycol Based Lubricants Market Research Report Companies for you to search.

Showing "Global Polyalkene Glycol Based Lubricants Market Research Report" News Articles 26–50 of 58,000+

Friday 22nd March 2019

ER Doc Survives Cancer, Now Must Survive ER

A Florida-based ER physician with an aggressive lymphoma underwent a 'miracle' treatment but now has a weakened immune system. Back at work, now he has to survive the ER and its germs. Medscape Medical News


Unfinished Business: LDT Legislation A Top Priority For Departing FDA Chief Gottlieb

In a farewell talk at the Brookings Institution, outgoing US FDA Commissioner Scott Gottlieb said a top unfinished business that...   

Cerveau Technologies Inc. Signs Research Agreement with Eisai Inc., for Novel Tau Imaging Agent

Cerveau Technologies, Inc. today announced a research collaboration agreement with Eisai Inc., which will enable Eisai to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are...


Over 3,000 more pharmacists needed in general practice to tackle GP shortages, says think tank report

A minimum of 3,000 extra pharmacists are needed in general practice across England by 2024 to help tackle rising patient demand and GP shortages, a report compiled by three major think-tanks warns.

FT Health: The UK’s chief medical officer on the NHS, drug resistance and global health

The UK’s chief medical officer on the NHS, drug resistance and global health

Childhood anxiety tied to school absences

(Reuters Health) - Kids with school attendance or truancy problems might be suffering from anxiety, a research review suggests.

Xpediant Digital Hires Steve Surace as VP of Product Development

Based on Product Demands, Xpediant expands Leadership Team with VP of Product Development HOUSTON, Texas (PRWEB) March 22, 2019 Xpediant Digital, the leader in DAM Integration Platforms, today announced that veteran technology leader Steve Surace has joined Xpediant as VP of Product Development. Surace has spent his career developing products, building complex solutions and world-class global tea...

Eisai Initiates Phase 3 Trial of BAN2401 in Early Alzheimer’s Disease

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced that a global Phase III clinical study (Clarity AD/Study 301) of BAN2401, an anti-amyloid beta protofibril antibody, in patients with early Alzheimer’s disease has been initiated. BAN2401 is being jointly developed by Eisai and Biogen Inc. (Headquarters: Cambridge, Massachusetts, United States, “Biogen”). Clar...

OPTIMA: your laboratory resources management

Optima is a web-based solution designed to ease one of the most cumbersome and time-consuming of laboratory managers’ tasks: resources planning... The post OPTIMA: your laboratory resources management appeared first on European Pharmaceutical Re

LegoChem and Takeda Partner for the Development of Antibody-Drug Conjugates in Immuno-Oncology

DAEJEON, South Korea–(BUSINESS WIRE)–LegoChem Biosciences, Inc. (“LCB”) (KOSDAQ:141080) announced today that it has entered a research collaboration and license agreement with Takeda Pharmaceutical Company Limited (“Takeda”) for the development of antibody-drug conjugates in immuno-oncology. Takeda gains certain rights to LCB’s antibody-drug conjugate (ADC) technology, C...

Human medicines European public assessment report (EPAR): Intrarosa, prasterone, Menopause, Date of authorisation: 08/01/2018, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Intrarosa, prasterone, Menopause, Date of authorisation: 08/01/2018, Revision: 2, Status: Authorised

FDA Warns About the Risks Associated with the Investigational Use of Venclexta in Multiple Myeloma

[3/21/2019] The U.S. Food and Drug Administration is alerting health care professionals, oncology clinical investigators and patients about the risks associated with the investigational use of Venclexta (venetoclax) for the treatment of patients with multiple myeloma based on data from a clinical trial. Venclexta is not approved for the treatment of multiple myeloma. FDA reviewed data …

OncLive® Presents State of the Science Summit™ on Ovarian Cancer and Soft Tissue Sarcoma

The summit will feature expert faculty from Memorial Sloan Kettering Cancer Center OncLive®, the nation’s leading digital resource focused on providing oncology professionals with the most current and insightful information they need to provide the best patient care, will host its latest State of the Science Summit™ on ovarian cancer and soft tiss...

Gottlieb: Valsartan API Crisis Spurs Drug GMP Revision

FDA commissioner discloses effort underway to tighten oversight of changes to active pharmaceutical ingredient manufacturing processes by rewriting parts of...   

Long-term use of inexpensive weight-loss drug may be safe and effective

An inexpensive weight-loss drug approved 60 years ago for only short-term use also may be safe and effective for longer-term treatment, according to a study conducted by researchers at Wake Forest Baptist Health and the Patient Outcomes Research to Advance Learning network.

Human medicines European public assessment report (EPAR): Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron), dinutuximab beta, Neuroblastoma, Date of authorisation: 08/05/2017, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron), dinutuximab beta, Neuroblastoma, Date of authorisation: 08/05/2017, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Zeffix, lamivudine, Hepatitis B, Chronic, Date of authorisation: 28/07/1999, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Zeffix, lamivudine, Hepatitis B, Chronic, Date of authorisation: 28/07/1999, Revision: 23, Status: Authorised

Coral Reefs Near Equator Less Affected by Ocean Warming

NewsResearch based on analysis of field observations from 20-year global coral survey.Contributed Author: 

AAAAI Installs New President, Dr. David Lang, at 2019 Annual Meeting

David M. Lang, MD, FAAAAI, is Chairman of the Department of Allergy and Clinical Immunology, Co-Director of the Asthma Center, and Director of the Allergy/Immunology Fellowship Training Program in the Respiratory Institute at the Cleveland Clinic. MILWAUKEE (PRWEB) March 22, 2019 The American Academy of Allergy, Asthma & Immunology (AAAAI) is pleased to introduce its 2019-2020 President, Davi...

UnitedHealthcare Launches National Vision Laboratory Network Relationship with Essilor Labs

UnitedHealthcare, a UnitedHealth Group (NYSE: UNH) company, has launched a national vision laboratory network to better serve eye care professionals and meet the needs of more than 19 million vision plan participants. The laboratory network has launched in collaboration with Essilor, which operates the largest optical lab network in the country. T...

USAWorldMeds Names Neurologist & Addiction Medicine Specialist Dr. Russell Surasky as Expert Speaker for New Ground-Breaking Medication Lucemyra

Lucemyra is the First FDA Approved Medicine to Treat Opioid Withdrawal Syndrome (OWS). GREAT NECK. N.Y. (PRWEB) March 22, 2019 “Not a day goes by when we don’t learn more about the devastation caused by opioid addiction. Every day in the United States approximately 4,000 individuals start using opiates for non-medical purposes. We are now up to about 130 opioid overdoses per day,” says Neur...

4D Printing Could Lead to Small, Implantable Medical Devices

Engineers at Rutgers University-New Brunswick report the creation of flexible, lightweight materials with 4D printing that could lead to small implantable biomedical devices, among other applications. Their study (“4D Printing Reconfigurable, Deployable and Mechanically Tunable Metamaterials”) appears in Materials Horizons. “Exotic properties of mechanical metamaterials emerge from the topol...

Merck Portfolio: Halftime Report

CCG report shows increase in emergency readmissions

NHS Digital has published emergency readmissions statistics for first time in five years.

uBiome Awards Grant to Nnamdi Azikiwe University to Study the Influence of Probiotics on the Urinary Tract Microbiome

Researchers will use the grant to investigate the effect of probiotics on the urinary tract microbiome. SAN FRANCISCO (PRWEB) March 22, 2019 uBiome has awarded microbiome research support in study design, planning, sample collection, and analysis to a team of researchers at Nnamdi Azikiwe University in Anambra State, Nigeria led by Dr. Kingsley C. Anukam, PhD, and supported by Dr. Nneka R. Agboko...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks